Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.2800
- TODAY'S CHANGE (%)-0.0400 (-1.2048%)
- Bid / Lots3.1500/ 3
- Ask / Lots3.5500/ 1
- Open / Previous Close3.3800 / 3.3200
- Day Range
- 52 Week Range
- Volume96,511
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 12024 | 3.38 |
| 09:33 ET | 20000 | 3.3698 |
| 09:37 ET | 200 | 3.32 |
| 09:44 ET | 8650 | 3.29 |
| 09:48 ET | 333 | 3.315 |
| 09:50 ET | 2432 | 3.32 |
| 09:51 ET | 2400 | 3.355 |
| 09:53 ET | 907 | 3.37 |
| 09:57 ET | 670 | 3.38 |
| 10:06 ET | 200 | 3.31 |
| 10:09 ET | 900 | 3.3554 |
| 10:27 ET | 100 | 3.335 |
| 10:31 ET | 4290 | 3.3 |
| 10:33 ET | 3250 | 3.275 |
| 10:40 ET | 290 | 3.245 |
| 10:42 ET | 200 | 3.24 |
| 10:44 ET | 104 | 3.25 |
| 10:45 ET | 561 | 3.29 |
| 10:49 ET | 150 | 3.3039 |
| 10:54 ET | 3000 | 3.31 |
| 10:56 ET | 1000 | 3.325 |
| 11:00 ET | 1800 | 3.3 |
| 11:02 ET | 100 | 3.3 |
| 11:03 ET | 2520 | 3.295 |
| 11:09 ET | 200 | 3.3 |
| 11:16 ET | 391 | 3.27 |
| 11:20 ET | 161 | 3.26 |
| 11:23 ET | 3710 | 3.2501 |
| 11:25 ET | 799 | 3.27 |
| 11:32 ET | 1439 | 3.33 |
| 11:34 ET | 188 | 3.33 |
| 11:50 ET | 100 | 3.3 |
| 11:54 ET | 141 | 3.29 |
| 11:59 ET | 400 | 3.285 |
| 12:10 ET | 100 | 3.27 |
| 12:19 ET | 100 | 3.26 |
| 12:24 ET | 100 | 3.26 |
| 12:28 ET | 587 | 3.27 |
| 12:32 ET | 100 | 3.27 |
| 12:35 ET | 100 | 3.28 |
| 12:39 ET | 1914 | 3.3 |
| 12:48 ET | 2189 | 3.29 |
| 12:50 ET | 201 | 3.29 |
| 12:55 ET | 200 | 3.28 |
| 12:57 ET | 200 | 3.265 |
| 01:00 ET | 3732 | 3.28 |
Nov 12, 2024
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib, from 7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 8, 2024
DJ Repare Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 11:46AM ET on Friday Nov 08, 2024 by Dow Jones
11:46AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
7:05AM ET on Thursday Nov 07, 2024 by Dow Jones*DJ Repare Therapeutics 3Q Loss/Shr 81c >RPTX, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 133.9M | -1.6x | --- |
Innate Pharma SA | 123.0M | -3.5x | --- |
Champions Oncology Inc | 58.6M | -17.8x | --- |
Cidara Therapeutics Inc | 142.3M | -0.8x | --- |
Precision BioSciences Inc | 54.5M | 9.5x | --- |
Adaptimmune Therapeutics PLC | 174.0M | -3.4x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes lunresertib (RP-6306), a PKMYT1 inhibitor in Phase 1/2 clinical development; camonsertib (RP-3500), a potential Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) inhibitor in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical polymerase theta adenosinetriphosphatase (ATPase) inhibitor program, and additional, undisclosed preclinical programs. RP-3500 is a potent and selective oral small molecule inhibitor of ATR in clinical development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $133.9M |
|---|---|
Revenue (TTM) | $66.5M |
Shares Outstanding | 42.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-2.00 |
Book Value | $5.03 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -140.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
